Key result
Lp(a) independently compounds ASCVD risk, which LDL-C lowering fails to fully offset.
Why the study?
The relationship between lipoprotein(a) level, low-density lipoprotein cholesterol level, and atherosclerotic cardiovascular disease risk at different thresholds is not well defined.
Do elevated Lp(a) levels increase ASCVD risk independently of achieved LDL-C levels in statin-treated patients?
Meta-Analysis (n=27,658)
Yes
Do elevated Lp(a) levels increase ASCVD risk independently of achieved LDL-C levels in statin-treated patients?
Answers are grounded in this paper and cite their sources.
Lp(a) and LDL-C levels are independent and additive predictors of ASCVD risk, demonstrating that LDL-C lowering with statins does not fully offset Lp(a)-mediated risk.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models. RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1-77.0 mg/dL), those with Lp(a) level >50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06-1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46-2.48]). CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2024) conducted a meta-analysis in Atherosclerotic cardiovascular disease (ASCVD) risk (n=27,658). Lp(a) level >50 mg/dL vs. Lp(a) level ≤50 mg/dL was evaluated on Fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD) (HR 1.38, 95% CI 1.06-1.79). Among statin-treated patients with the lowest achieved LDL-C, Lp(a) >/dL was associated with higher ASCVD risk compared to Lp(a) ≤/dL.
Synapse has enriched 10 related papers. Consider them for comparative context: